I
INmune Bio Inc. (INMB)
NCM – Real vaqt narxi. Valyuta: USD
2.06
-0.03 (-1.20%)
Bozor ochiq: Aug 12, 2026, 2:37 PM EDT
2.13
+0.05 (2.40%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.06
-0.03 (-1.20%)
Bozor ochiq: Aug 12, 2026, 2:37 PM EDT
2.13
+0.05 (2.40%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
INmune Bio Inc., klinik bosqichdagi immunologiya kompaniyasi, Qo'shma Shtatlarda kasalliklarni davolash uchun bemorlarning tug'ma immunitet tizimini qayta dasturlash uchun dori vositalarini ishlab chiqishga qaratilgan. Kompaniya gematologik malignliklar, qattiq o'smalar va surunkali yallig'lanishni davolash uchun mahsulot nomzodlarini ishlab chiqish va tijoratlashtirishni maqsad qilgan. Kompaniyaning ishlab chiqish dasturlari orasida yuqori xavfli mielodisplastik sindromga chalingan bemorlarni davolash uchun 1-bosqichda bo'lgan INKmune; va ko'krak bezi saratonini davolash uchun 2-bosqichda bo'lgan INB03 mavjud. Kompaniya Altsgeymer kasalligi va davolashga chidamli depressiyani davolash uchun XPro1595; va tomir ichiga yuborish yoki in'ektsiya qilish uchun aseptik, allogenik va aralashtirilgan HucMSClar dan iborat hujayra suspenziyasi bo'lgan CORDstromni taqdim etadi. Kompaniya Xencor, Inc.; Immune Ventures, LLC; GOSH; va Pitsburg universiteti bilan litsenziya shartnomalariga ega. Kompaniya 2015-yilda tashkil etilgan va shtab-kvartirasi Florida shtatining Boca Raton shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Mark William Lowdell Ph.D. | Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer |
| Mr. Cory Randall Ellspermann | Interim Chief Financial Officer |
| Mr. Daniel Frederick Carlson | Head of Investor Relations |
| Mr. David J. Moss M.B.A. | President, CEO, Treasurer, Secretary & Director |
| Mr. Joshua S. Schoonover Esq. | General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 10-Q | ea0298894-10q_inmune.htm |
| 2026-07-31 | 8-K | ea0300069-8k_inmune.htm |
| 2026-07-01 | 8-K | ea0296624-8k_inmune.htm |
| 2026-06-23 | 8-K | ea0295635-8k_inmune.htm |
| 2026-06-17 | 8-K | ea0295129-8k_inmune.htm |
| 2026-06-02 | 8-K | ea0293325-8k_inmune.htm |
| 2026-05-14 | 8-K | ea0290846-8k_inmune.htm |
| 2026-05-07 | 10-Q | ea0287417-10q_inmune.htm |
| 2026-05-05 | 8-K | ea0288685-8k_inmune.htm |
| 2026-04-23 | DEF 14A | ea0286340-01.htm |